Skip to main content

Change in PDL Status for the Macrolides-Ketolides Drug Class Effective November 7, 2023

Last updated on

In response to the shortage of the preferred brand name product Eryped 200 MG/5 ML suspension, the Texas Health and Human Services Commission (HHSC) has removed the non-preferred status from the generic erythromycin 200 MG/5 ML and E.E.S. 200 MG/5 ML suspension products on the preferred drug list (PDL).

Note: The preferred status of the brand name Eryped 200 MG/5 ML suspension with National Drug Code (NDC) 24338013213 will not change so that any existing stock may be used.

Effective November 7, 2023, HHSC removed the non-preferred status of the following products to allow providers to prescribe generic erythromycin 200 MG/5 ML and E.E.S. 200 MG/5 ML suspension without requiring a PDL prior authorization. This allows clients to continue accessing the necessary medication.

The table below lists the erythromycin products with their NDCs.

NDCDrug Name
62559044001Erythromycin 200 MG/5 ML Suspension
62559044002Erythromycin 200 MG/5 ML Suspension
62559063001Erythromycin 200 MG/5 ML Suspension
69238150301Erythromycin 200 MG/5 ML Suspension
75834029501Erythromycin 200 MG/5 ML Suspension
24338013402E.E.S. 200 MG/5 ML Suspension
24338013610E.E.S. 200 MG/5 ML Suspension

Email vdp-formulary@hhsc.state.tx.us with comments or questions.